Vaccine Storage Solutions

Researchers at Penn State University have discovered a new storage technique that stabilizes #protein-based drugs and #vaccines without the need for refrigeration, potentially transforming their accessibility and affordability. Over 80% of biologic drugs and 90% of vaccines typically require temperature control. This innovative method aims to eliminate the costly cold chain logistics that currently amount to an estimated $58 billion globally by 2026, according to Scott Medina, study lead and Professor of Biomedical Engineering at Penn State. The research, published in Nature Communications, involves replacing the conventional water-based solution with a sterile perfluorocarbon oil, which has been tested on various proteins, including #antibodies and #enzymes. These proteins maintained their effectiveness and showed no toxicity in mice, demonstrating the oil's safety. The challenge of protein solubility in oil was addressed by developing a #surfactant that coats the proteins, allowing them to disperse evenly while providing a protective shell that enhances stability at high temperatures up to 212°F. This new method could facilitate the distribution of protein therapies in environments lacking refrigeration, such as remote areas and battlefield settings. The researchers plan to further validate this approach with additional proteins and collaborate with pharmaceutical companies to enhance the stability of protein-based medications. They are also in the process of securing patent rights for their discovery. https://lnkd.in/err52dQc The team includes Girish Kirimanjeswara, associate professor of veterinary and biomedical science; Atip Lawanprasert, Mariangely González Vargas and Arishya Dewan, Penn State graduate students; as well as Dr. Harminder Singh, postdoctoral scholar; and Sopida Pimcharoen, undergraduate student. https://lnkd.in/err52dQc

Something's happening up in Boulder, and it's not another craft beer startup, it's VitriVax turning #vaccinescience into something out of a sci-fi novel. This isn't your standard biotech story; it's what happens when a virologist and an engineer decide #coldstorage is a problem worth eliminating and build an entire platform around it. Co-founders Bob Garcea and Ted Randolph took the kind of academic collaboration most people write papers about and turned it into a company that's now redefining how vaccines survive the real world. VitriVax just locked in $17.25M in Series B funding, co-led by Adjuvant Capital and RA Capital Management. Add that to a $9.9M Gates Foundation grant earlier this month, $5M from CEPI (Coalition for Epidemic Preparedness Innovations) for rabies work, $3.6M from Gates for polio, and a $29M #DoD contract, and you start to see the pattern. When every heavyweight in #globalhealth and #defense lines up behind your tech, you're not pitching potential, you're proving it. CEO Romulo Colindres isn't new to this arena. Fifteen years in vaccines, former VP of Global Medical Affairs for GSK's zoster vaccine, MD/MPH/MBA credentials that read like a clinical manual for execution. Add VP of Operations Kimberly Erickson, Ph.D., leading the $28M DTRA contract, and you've got a leadership core that blends scientific depth with operational precision. They've grown from 19 employees to more than 50 in just 3 years, proof that momentum follows substance. The science? The ALTA® platform, Atomic Layering Thermostable Antigen and Adjuvant, isn't just a cool acronym; it's the kind of tech that laughs in the face of 70°C heat. Imagine a single shot that carries its own #booster, stable for months without a cold chain, designed for places where "#refrigeration" means a cooler under a tree. Spray-dried #antigens sealed in sugar glass, nanometer coatings controlling release timing like a metronome. It's elegant #chemistry meeting real-world logistics. This $17.25M round fuels ALTA's march toward human clinical trials, scaling GMP manufacturing and regulatory readiness. VitriVax's HQ at 5500 Central Ave, Boulder is becoming the launchpad for a new era where vaccines travel better than tourists. Partnerships with the Serum Institute of India Pvt. Ltd., University of Nevada, Reno, and Latham Biopharm Group (aka Biopharm Services name changed) back that mission with serious muscle. VitriVax is solving a logistics problem that's haunted global health for decades. The world doesn't need more vaccines, it needs vaccines that can survive the trip. That's the quiet revolution happening in Boulder, funded by believers and built by people who refuse to let refrigeration decide who gets protection. #Startups #StartupFunding #VentureCapital #SeriesB #Biotech #Vaccine #VaccineTech #Healthcare #HealthTech #Technology #Innovation #TechEcosystem #StartupEcosystem If software engineering peace of mind is what you crave, Vention is your zen.

Imagine a health worker arriving at a community health center only to find that vaccines – which must be kept at the right temperature to be effective – have spoiled due to a lack of refrigeration. In regions with unreliable power, this is a harsh reality.  “Solar-powered” refrigerators are changing that.  These units (see the blue fridge in the photo below) connect to solar panels installed on clinic rooftops instead of relying on batteries or fuel, which keeps vaccines at the right temperature and ensures immunizations continue – even in the most remote areas or when power is disrupted, such as during cyclones and other climate-induced emergencies. Thanks to partners like Gavi, the Vaccine Alliance and UNICEF, these innovations are making a real impact. Continued investment in solutions like this means fewer wasted vaccines and more children are protected from deadly diseases.  Read more about how these fridges are making a difference in countries like Malawi: https://lnkd.in/gWYKRQ87

Three Indian teenagers — Dhruv Chaudhary, Mithran Ladhania, and Mridul Jain — from Shishukunj International School in Indore have developed an innovative electricity free portable refrigerator called Thermavault, which earned them the Earth Prize Asia 2025 and a reward of twelve thousand five hundred dollars. This unique fridge works without any compressor or electrical power, using salt based endothermic reactions. When certain salts dissolve in water, they absorb heat from the surroundings, thus cooling the contents of the fridge. This invention is a game changer for regions with unreliable power supply. The Thermavault design includes an insulated plastic outer shell and a copper lined inner chamber. The space between them holds water mixed with salts like ammonium chloride (for regular cooling) and barium hydroxide octahydrate (for freezing conditions). It is especially useful for storing vaccines and medicines in rural healthcare settings. Local doctors reported that the prototype could keep vaccines cold for ten to twelve hours under real world conditions. The team plans to build two hundred units for field trials in more than one hundred hospitals and seeks World Health Organization approval to make it a global healthcare solution.

A single degree of temperature variation can turn a life-saving vaccine into worthless liquid. This harsh reality hit me early in my career when a batch of vaccines lost potency due to poor storage. The financial loss was painful, but imagining the patients who missed their protection was devastating. That's why we invested in advanced ultra-cold storage facilities. Yes, it was expensive. Our extensive cold storage infrastructure with round-the-clock power backup wasn't cheap. Training our entire delivery team in proper handling protocols cost money. But when I see a pediatrician confidently administering our vaccines, knowing they're fully effective, I realize we didn't spend money - we invested in lives. After decades in pharmaceutical distribution, I've learned that quality isn't a cost center, it's our promise. Because when someone's recovery depends on the medicine we deliver, compromise isn't an option. Quality saves lives. And lives? They're priceless. #healthcare #pharmaindustry #medicine

The Vaccine Ice Age Is Over: Stablepharma’s Fridge-Free Tech Could potentially Upend Global Immunization Forever Stablepharma’s StablevaX™ technology has stunned the global vaccine industry by enabling thermostable delivery of a tetanus-diphtheria vaccine—retaining full potency after 10 months at 45°C. This fridge-free breakthrough could revolutionize immunization logistics, especially in low-resource settings, and drastically reduce cold-chain costs and wastage. With over 60 temperature-sensitive vaccines identified as candidates, the platform is poised to reshape global vaccine access. While its use for monoclonal antibodies and other biologics remains under exploration, StablevaX™ signals a disruptive shift that may soon extend beyond vaccines. https://lnkd.in/ew-dY-Db